

A synthetic compound that potentiates bone morphogenetic protein-2-induced transdifferentiation of myoblasts into the osteoblastic phenotype

メタデータ	言語: eng 出版者: 公開日: 2017-10-03 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	<a href="http://hdl.handle.net/2297/27096">http://hdl.handle.net/2297/27096</a>

Editorial Manager(tm) for Molecular and Cellular Biochemistry  
Manuscript Draft

Manuscript Number: mcbi-3640R1

Title: A Synthetic Compound that Potentiates Bone Morphogenetic Protein-2 Induced Transdifferentiation of Myoblasts into the Osteoblastic Phenotype

Article Type: Original Research

Keywords: BMP-2; Smad; Smurf1; Virtual Screening; potentiating

Corresponding Author: Sreedhara Sangadala, Ph.D

Corresponding Author's Institution:

First Author: Satoshi Kato

Order of Authors: Satoshi Kato;Sreedhara Sangadala, Ph.D;Katsuro Tomita;Louisa Titus;Scott D Boden

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**A Synthetic Compound that Potentiates Bone Morphogenetic Protein-2  
Induced Transdifferentiation of Myoblasts into the Osteoblastic Phenotype**

Satoshi Kato<sup>¥1,2</sup>, Sreedhara Sangadala<sup>¥1\*</sup>, Katsuro Tomita<sup>2</sup>, Louisa Titus<sup>1</sup> and  
Scott D. Boden<sup>1</sup>

<sup>1</sup>Atlanta VA Medical Center and Department of Orthopaedics, Emory University  
School of Medicine, Atlanta, Georgia 30329

<sup>2</sup>Department of Orthopaedic Surgery, Kanazawa University School of Medicine  
Kanazawa, 920-8641, Japan

¥contributed equally

\*corresponding author:  
Sreedhara Sangadala  
VAMC-Research Service  
1670 Clairmont Rd.  
Decatur, GA 30033  
Phone: 404-321-6111 x 2539  
Fax: 404-728-7780  
Email: [ssangad@emory.edu](mailto:ssangad@emory.edu)

Running title: Osteogenic activity of a synthetic compound

## ABSTRACT

There is an urgent need to develop methods that lower costs of using recombinant human bone morphogenetic proteins (BMPs) to promote bone induction. In this study, we demonstrate the osteogenic effect of a low molecular weight compound, SVAK-12, that potentiated the effects of BMP-2 in inducing transdifferentiation of C2C12 myoblasts into the osteoblastic phenotype.

Here we report a specific compound, SVAK-12, which was selected based on *in silico* screenings of small molecule databases using the homology modeled interaction-motif of Smurf1-WW2 domain. The enhancement of BMP-2 activity by SVAK-12 was characterized by evaluating a BMP-specific reporter activity and by monitoring the BMP-2-induced expression of mRNA for osteocalcin and alkaline phosphatase which are widely accepted marker genes of osteoblast differentiation. Finally, we confirmed these results by also measuring the enhancement of BMP-2-induced activity of alkaline phosphatase.

Smurf1 is an E3 ligase that targets osteogenic Smads for ubiquitin mediated proteasomal degradation. Smurf1 is an interesting potential target to enhance bone formation based on the positive effects on bone of proteins that block Smurf1-binding to Smad targets or in Smurf1<sup>-/-</sup> knockout mice. Since Smads bind

1  
2  
3  
4  
5  
6  
7 Smurf1 via its WW2 domain, we performed *in silico* screening to identify  
8  
9  
10 compounds that might interact with the Smurf1 Ww2 domain. We recently reported  
11  
12 the activity of a compound, SVAK-3. However, SVAK-3, while exhibiting  
13  
14 BMP-potentiating activity, was not stable and thus warranted a new search for a  
15  
16 more stable and efficacious compound among a selected group of candidates. In  
17  
18 addition to being more stable, SVAK-12 exhibited a dose-dependent activity in  
19  
20 inducing osteoblastic differentiation of myoblastic C2C12 cells even when multiple  
21  
22 markers of the osteoblastic phenotype were parallelly monitored.  
23  
24  
25  
26  
27  
28  
29

30 **Key Words:** BMP-2, Smad, Smurf1, Virtual Screening, potentiating  
31  
32

33  
34 **Abbreviations:** bone morphogenetic protein, BMP; Smad Ubiquitin Regulatory  
35  
36 Factor-1, Smurf1; Reverse transcriptase- polymerase chain reaction, RT-PCR;  
37  
38 alkaline phosphatase, ALP; dimethylsulfoxide, DMSO; Relative Units of Luciferase,  
39  
40 RUL; fetal bovine serum, FBS, Chemicals available for purchase-database, CAP  
41  
42  
43  
44  
45 database.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## INTRODUCTION

The process of cell differentiation is regulated by several cytokines. Among the osteogenic proteins that have been reported, the Bone Morphogenetic Protein (BMP) family members are the most notable cytokines for their unique ability to promote differentiation of mesenchymal stem cells and pre-osteoblastic cells into osteoblasts *in vitro* and also to induce ectopic bone formation *in vivo* [1]. Recombinant human BMP-2 was approved by the FDA in 2002 and is being used clinically as a bone graft substitute to achieve spinal fusion and fracture repair. However the requirement for a 15,000-fold higher concentration in humans (1.5 mg/ml) than in cell culture (100 ng/ml) creates a huge translational barrier for routine clinical use due to high cost [2-6]. In this study, we describe a compound that exhibits a strong potentiating activity on BMP-2.

Smurf1 disruption is a potential therapeutic strategy to increase BMP responsiveness. Interest in Smurf1 as a target is supported by the observation that *Smurf1*<sup>-/-</sup> mice exhibit an age-dependent increase in bone mass [7]. Smurf1 transgenic mice showed decreased bone volume and a reduced bone formation rate [8]. LIM Mineralization Protein-1 (LMP-1) can enhance BMP-2 activity by increasing cellular responsiveness to BMP-2 [9, 10]. LMP-1 exerts at least a part of this effect by interacting with the E3 ligase, Smurf1, preventing binding and

1  
2  
3  
4  
5  
6  
7 degradation of Smads 1, 5 and 8 [9]. We modeled the binding domains of Smurf1  
8  
9 and its Smad target peptides in a recent report [11, 12]. Our overall goal is to  
10  
11 translate our knowledge of the modeled Smurf1-WW2 domain structure into  
12  
13 therapeutic applications for clinical bone-induction. Unlike recombinantly prepared  
14  
15 proteins or synthetic peptides, the use of drug-like, low molecular weight  
16  
17 compounds has several advantages, including blocking all the activity mediated by  
18  
19 the Smurf1 WW2 domain, better cell permeability, and better *in vivo* stability and  
20  
21 bioavailability. In this report, compounds that were selected by virtual screening, are  
22  
23 evaluated for their osteogenic activity for their potential use as drugs that promote  
24  
25 BMP-2 activity. In this report, compounds that were selected by virtual screening, are  
26  
27 evaluated for their osteogenic activity for their potential use as drugs that promote  
28  
29 BMP-2 activity.  
30  
31  
32  
33  
34

35 In this study, we focus on identifying a low molecular weight compound as  
36  
37 a reagent that potentiates BMP-2 activity from a set of lead compounds that were  
38  
39 previously selected based on computational homology modeling [11], docking, and  
40  
41 *in silico* screening of commercially available small molecular compounds. The  
42  
43 selected compounds were predicted to possess features similar to the PPXY motif  
44  
45 of Smads that interact with Smurf1, as determined by Ludi docking scores. The  
46  
47 BMP-potentiating activities of the compounds were evaluated by monitoring several  
48  
49 markers of the osteoblastic phenotype corresponding to various time points during  
50  
51 phenotype differentiation of C2C12 cells towards terminally differentiated  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 osteoblasts. We used this phenotypically stable cultured cell line as an *in vitro*  
8 model system to study inducible effects in which the direct change is differentiation.  
9  
10 The extremely low cost of SVAK-12 and its high stability and availability make it  
11  
12 appealing for use in bone regenerative medicine. Our findings serve as a basis to  
13  
14 formulate new therapeutic approaches in which the use of BMP is more affordable.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## MATERIALS AND METHODS

### *Cell culture*

Mouse C2C12 cells and Dulbecco's modified Eagle's medium (DMEM) were purchased from ATCC (Manassas, VA). The non-heat inactivated fetal bovine serum (FBS) was purchased from HyClone Laboratories, Inc. (Logan, UT). The C2C12 cells at passages 5 to 10 were subcultured in T-75 cm<sup>2</sup> flasks in DMEM supplemented with 10 % FBS at 37°C in 5 % CO<sub>2</sub> with humidification. When the flasks reached 80 % confluence, the cells were trypsinized and seeded in triplicate at 200,000 cells/well in a 6-well plate for quantitative real-time RT-PCR and alkaline phosphatase (ALP) assays or at 50,000 cells/well in a 12-well plate for the dual-luciferase reporter assay.

### *In silico screening of small molecular databases*

We used the chemical database (Chemicals Available for Purchase- CAP) (Accelrys Inc.) for compound screenings. We accessed 70,000 molecules in the database supplied by Accelrys Inc. The WW2-domain structure of Smurf1 served as a model for receptor-based *in silico* screenings. The screening was performed using the program LUDI, *de novo* receptor docking procedure. LUDI, which can be considered as a hybrid of a complete pharmacophore and 3D modeling tool, is a

1  
2  
3  
4  
5  
6  
7 method for the *de novo* design and positioning of ligands for proteins [13, 14]. The  
8  
9 LUDI score is a sum of five contributions: ideal hydrogen bonds, perturbed ionic  
10  
11 interactions (interaction of donor/acceptor in the receptor, e.g. COO<sup>-</sup>, or NH<sub>3</sub><sup>+</sup>),  
12  
13 lipophilic interactions, the freezing of internal degrees of freedom of the ligand, and  
14  
15 the loss of translational and rotational entropy of the ligand. In receptor mode, LUDI  
16  
17 searches a fragment library for complementary small molecules that best bind the  
18  
19 defined interaction sites. During the “search and fit” the LUDI program also  
20  
21 determines the energy estimates, or scores, for each conformation of the selected  
22  
23 fragments in the library.  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Each molecule in our databases with a molecular weight between 200 and  
34  
35 700 was docked into the targeted binding site in the WW2 domain of Smurf1. Based  
36  
37 on the binding models of these compounds predicted by LUDI, the top 10% of the  
38  
39 high scoring compounds from the CAP database were extracted. This output was  
40  
41 further refined by excluding redundant analogs of the same scaffold. Of the  
42  
43 best-scored 300 compounds selected, samples of 54 compounds were obtained  
44  
45  
46  
47  
48 from different vendors.  
49  
50  
51  
52

53 *RNA extraction and reverse transcription*  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 The C2C12 cells were plated at a density of 200,000 cells/well in 6-well  
8 plates and grown overnight in DMEM containing 10% FBS. On day 2, the culture  
9 medium was replaced with DMEM containing 2 % FBS and the cells were treated  
10 with various concentrations of selected compound (diluted from 10 mg/ml stock  
11 solutions prepared in DMSO) for 24 hours. In control cultures, a DMSO solvent  
12 concentration of 0.01% (v/v) was applied. On day 3, medium was replaced with  
13 fresh DMEM containing 2% FBS and the cells were treated with BMP-2 for 24  
14 hours.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Total RNA was harvested using the RNeasy Mini Kit according to the  
31 manufacturer's instructions (Qiagen, Valencia, CA). The harvested RNA was  
32 digested with RNase-free DNase I (Qiagen, Valencia, CA) to remove DNA  
33 contamination. The concentration of the isolated RNA was determined by  
34 measuring the absorbance at 260 nm wave length with a spectrophotometer (Model  
35 DU 640, Beckman Coulter, Inc. Brea, CA). The ratio of A260/A280 was between 1.6  
36 and 1.8. Reverse transcription was carried out to synthesize cDNA in a 100  $\mu$ l  
37 volume with 2  $\mu$ g of total RNA, 10 $\times$ RT buffer, 5.5 mM MgCl<sub>2</sub>, 2 mM dNTP mixture,  
38 0.125  $\mu$ M oligo d(T), 0.125  $\mu$ M random primer, 40 Units of RNase inhibitor, and 125  
39 Units of MultiScribe (Applied Biosystems, Foster City, CA) for 10 minutes at 25°C,  
40 30 minutes at 48°C, and 5 minutes at 95°C.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### *Quantitative real-time RT-PCR*

Quantitative real-time RT-PCR was performed to determine the mRNA expression level of ALP and osteocalcin. The sequences of the primers were as follows: ALP (forward, 5'-TCA GGG CAA TGA GGT CAC ATC-3'; reverse, 5'-CAC AAT GCC CAC GGA CTT C-3'), osteocalcin (forward, 5'-CGG CCC TGA GTC TGA CAA AG-3'; reverse, 5'-CTC GTC ACA AGC AGG GTC AA-3'). Twenty-five microliters of reaction volume included 5  $\mu$ l of cDNA, 0.5  $\mu$ l of 10  $\mu$ M of each primer and 12.5  $\mu$ l of 2 $\times$ SYBR green master mix (Applied Biosystems). Real-time PCR was performed with the following three-step protocol: step 1, 50°C for 2 minutes; step 2, 95°C for 10 minutes; step 3, 40 cycles of 95°C for 15 seconds and 62°C for 1 minute using the 7500 real-time PCR System (Applied Biosystems, Foster City, CA). To confirm the amplification specificity, the PCR products were subjected to a dissociation curve analysis. The threshold cycles (Ct) of each reaction were normalized to those obtained for 18S mRNA using the  $^{-\Delta\Delta}$ Ct method (Applied Biosystems). All PCR reactions were performed in triplicate.

### *Alkaline phosphatase (ALP) assay*

The C2C12 cells were plated at 200,000 cells/well in 6-well plates and grown overnight in DMEM containing 10% FBS. On day 2, the culture medium was

1  
2  
3  
4  
5  
6  
7 replaced with DMEM containing 2 % FBS and the cells were treated with various  
8 concentrations of compound for 24 hours. On day 3, the medium was replaced with  
9 fresh DMEM containing 2% FBS and the cells were treated with 50 ng/ml of BMP-2  
10 for 72 hours. The cells were washed with phosphate-buffered saline (PBS) and  
11 lysed by addition of lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM MgCl<sub>2</sub> and 0.5 %  
12 Triton X-100). The cell lysates were centrifuged for 5 minutes at 13,000 x g. The  
13 supernatant was removed and the aliquots were assayed for ALP activity and  
14 protein amount. The ALP activity was measured in triplicate using an ALP assay kit  
15 (Sigma-Aldrich, St. Louis, MO) in microtiter plates. The protein amount was  
16 determined with Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA) using  
17 bovine serum albumin (BSA) as a standard. The ALP activity (nmoles of  
18 p-nitrophenol per ml) was normalized to the protein amount (nmoles of  
19 p-nitrophenol per µg).

#### 42 43 *Dual -luciferase reporter assay*

44  
45  
46  
47 The BMP-specific Smad1-driven 9×GCCG (a consensus binding  
48 sequence for Smad1) reporter plasmid was kindly provided by Dr. Miyazono (The  
49 Institute of Japanese Foundation for Cancer Research, Tokyo). The C2C12 cells  
50 were trypsinized and seeded in triplicate wells at 50,000 cells/well in 12-well plates  
51 on day 1. On day 2, the cells were cotransfected with the 9×GCCG-reporter construct  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 and the renilla-luciferase control vector using SuperFect (Qiagen, Valencia, CA) for  
8  
9  
10 24 hrs. A total of 1 µg of plasmids was used for cotransfection in each well and the  
11  
12 concentration of renilla-luciferase vector was 1/15 of the 9×GCCG-reporter plasmid.  
13  
14  
15 On day 3, medium was replaced with DMEM containing 2% FBS and the cells were  
16  
17 treated with various concentrations of compound. On day 4, the cells were treated  
18  
19 with BMP-2. On day 5, the luciferase activities were measured in 20 µl of cell-lysate  
20  
21 using the dual-luciferase assay system (Promega, Madison, WI) with a luminometer  
22  
23 (LumiCount; Packard Bioscience, Meriden, CT) following the manufacturer's  
24  
25 instructions. The luciferase activity was expressed as relative units of luciferase  
26  
27 (RUL; a ratio of firefly luciferase to renilla luciferase activity).  
28  
29  
30  
31  
32  
33  
34

### 35 *Statistics and calculations*

36  
37  
38  
39

40 Results are presented as the mean of 3 determinations (n) with error bars  
41  
42 representing the standard error of the mean (SEM). Experimental results that are  
43  
44 visually represented are from consistent experiments where one representative  
45  
46 experimental result is shown. Statistical significance ( $P < 0.05$ ) was calculated using  
47  
48 a one-way analysis of variance (ANOVA) with Bonferroni Post Hoc test (equal  
49  
50 variances assumed) or Dunnett's T3 Post Hoc test (equal variances not assumed)  
51  
52 using Statistical Products for Social Sciences Version 16.0 (SPSS 16.0) for  
53  
54 Windows (SPSS, Chicago, IL) to compare various treatments in multi-group  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 analysis. Statistical probability of  $P < 0.05$  was considered significant and is denoted  
8 as (\*) in the figures.  
9

#### 10 11 12 13 14 *Determination of EC<sub>50</sub>* 15

16  
17  
18 The EC<sub>50</sub> values were calculated by determining the concentration by  
19 which 50% of maximum activity was reached using the sigmoidal fit equation. The  
20  
21 50% effective concentrations were determined with the standard curve analysis of  
22  
23 SigmaPlot 8.02. The nonlinear regression equation is  $y =$   
24  
25  $\text{min} + (\text{max} - \text{min}) / (1 + (x / \text{EC}_{50})^{\text{Hill Slope}})$  where y is the observed responses; x is the dose  
26  
27 concentration; max and min are approximated by the program automatically during  
28  
29 the calculation. Values were not extrapolated beyond the tested range of  
30  
31 concentrations.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## RESULTS

### *Modeling and assignment of template structure to a Smurf1-interacting peptide and its target Smurf1-WW2 domain*

Smurf1 interaction with Smads is based on the presence of unique residues in WW2-domain of Smurf1 (**Fig. 1**) [11, 12]. These observations prompted us to embark on a drug design project based on the interacting domain of Smurf1.

Since X-ray crystallographic or NMR-based structural data are lacking for the Smurf1 WW2 domain but homologous structures are available in the protein data bank, we used the homologous structures to discern a template model structure for the Smurf1 WW2 domain. The WW-domains are mined from the SWISS-PROT and SP-TrEMBL protein databases. We applied the „FindPattern’ function in the Genetics Computer Group (GCG) software to search in databases for related „chordate’ sequences for the Smurf1 WW2 domain. Modeling of a template structure for interacting domains is a critical pre-requisite for the subsequent identification of interacting residues. We accomplished this task for the Smad motif that interacts with Smurf1 [11]. We determined the model structure for the WW2-domain of Smurf1 and a Smurf1-interacting peptide motif as an example of Smurf1 target peptide (**Fig. 2**). To build template models, we used MODELLER



1  
2  
3  
4  
5  
6  
7 as well as SWISS\_MODEL [15, 16] protein structure homology modeling servers  
8 (accessible via the ExPasy server at <http://swissmodel.expasy.org>). We also used  
9  
10 the HOMOLOGY module of the INSIGHT-II software of Accelrys Inc. to model the  
11  
12 the HOMOLOGY module of the INSIGHT-II software of Accelrys Inc. to model the  
13  
14 target peptide structure. The HOMOLOGY module of INSIGHT-II helps in  
15  
16 extracting the equivalent coordinates of the similar structure to build a model  
17  
18 structure for the WW2-domain. Once a backbone and side chains of the target  
19  
20 peptide were built, we optimized the structure using the energy minimization  
21  
22 protocol of the DISCOVER module of INSIGHT-II. In order to model the  
23  
24 conformation of the target peptide, we used the related peptide fragment from the  
25  
26 rat Enac Bp2 peptide complex (1I5H, PDB code). This complex has a WW domain  
27  
28 bound to a peptide fragment that is similar to the N-terminal 10 residues of a  
29  
30 10-residue model peptide that interacts with Smurf1, with three prolyl residues  
31  
32 complexed with a homologous WW domain [11, 12]. The resultant model of the  
33  
34 ten residue structure was considered as an example of Smurf1 target proteins.  
35  
36 We compared these template models to obtain an acceptable model based on  
37  
38 evaluation by the WHAT-CHECK and PRO-CHECK programs to correct the errors.  
39  
40 These methods yielded optimum structure with stereochemically and energetically  
41  
42 favored configuration.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54  
55  
56 *Virtual screening and selection of compounds*  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 The LUDI *de novo* design method of Accelrys Inc. was used to identify the  
8  
9 compounds that potentially block the Smurf1-WW2 domain. The important binding  
10  
11 region within the WW2 domain was identified based on various studies on WW  
12  
13 domains in the literature. The region around the residues: Tyr<sub>18</sub>, Val<sub>20</sub>, His<sub>22</sub>, Arg<sub>25</sub>,  
14  
15 Thr<sub>27</sub> and Phe<sub>29</sub> was defined as the binding site with an appropriate radius of 9Å for  
16  
17 LUDI docking covering the entire binding interface (**Fig. 2**). The LUDI search  
18  
19 against the region gave about 400 molecules with a Ludi score greater than 300. In  
20  
21 **Fig. 2**, we show a cluster of 10 top scoring molecules that occupy the binding region.  
22  
23 The Ludi scoring approach was used to select 300 top scoring molecules. From  
24  
25 these, we obtained 54 compounds from commercial sources for biochemical  
26  
27 evaluation in living cells. Binding poses of 4 anonymous compounds are shown in  
28  
29 **Fig. 3**.

### 40 *Optimization of a cell-based method to monitor BMP-2 induced responses*

41  
42  
43  
44 The mouse-derived C2C12 myoblasts served as an experimentally  
45  
46 tractable model system for investigating the molecular basis of transdifferentiation  
47  
48 towards the osteoblastic phenotype. We recently developed a sensitive and reliable  
49  
50 cell-based assay utilizing a Smad1-specific luciferase reporter plasmid containing a  
51  
52 multimerized –GCCG- motif (9 copies) to monitor transcriptional activity driven by  
53  
54 activated Smad1 in C2C12 cells [17]. The BMP-specific Smad1-driven 9×GCCG  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 reporter construct has been widely used to assay BMP activity in many cell types at  
8  
9 a typical concentration of 50-100 ng/ml of BMP-2. To select a sub-optimal dose of  
10  
11 BMP-2 for studying the potentiating effect of selected compounds, we performed  
12  
13 the reporter assay with lower BMP-2 concentrations ranging from 0.25 to 25 ng/ml.  
14  
15 The concentration range of BMP-2 required for activating the reporter assay was  
16  
17 established (**Fig. 4**). The results from this experiment allowed us to select a  
18  
19 sub-optimal dose (1.0 ug/ml) of BMP-2 to assess the potentiating effects of  
20  
21 compounds in subsequent experiments.  
22  
23  
24  
25  
26  
27  
28  
29

#### 30 *SVAK-12 potentiates BMP-2 induced Smad1-driven luciferase reporter activity*

31  
32  
33

34 In an effort to identify a novel small drug-like molecule that could disrupt  
35  
36 Smurf1-Smad1/5 interaction we used the computer simulation techniques of  
37  
38 molecular docking for virtual screening. Compounds were ranked according to their  
39  
40 relative binding energy, favorable shape complementarity, and potential to form  
41  
42 hydrogen bonds within the modeled Smurf1 WW2 domain hydrophobic pocket [11,  
43  
44 12]. For each docked compound, the best-scoring complexes were ranked,  
45  
46 clustered, and re-ranked using calculations which included more accurate estimates  
47  
48 of desolvation. Finally, a diversity selection, followed by visual inspection using 3D  
49  
50 stereo-graphics of putative compounds, were employed as filters for discovery of  
51  
52 potential "lead" compounds. A representative sample of the most favorable  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 compounds (54 compounds) was tested experimentally for their ability to potentiate  
8 BMP-2 activity in our luciferase reporter assay using C2C12 cells. Out of these  
9 candidate lead compounds, we selected SVAK-12 for the current studies as a  
10 promising synthetic compound (**Fig. 5A and 5B**). We focused on additional  
11 characterization of SVAK-12 activity because it showed relatively higher activity and  
12 its parent compound and the related chemical derivatives were pharmacologically  
13 more defined. The solvent dimethylsulfoxide (DMSO) controls showed only basal  
14 activity similar to no treatment controls. The DMSO solvent concentration of 0.01%  
15 (v/v) was not toxic to cells as determined by cell number, total protein amount and  
16 cell phenotype consistent with the literature (data not shown). At concentrations  
17 higher than 1.0 ug/ml, SVAK-12 caused lifting of cells from plates leading to  
18 decreased number of cells at the end of the experiment.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Next, we determined the effectiveness of compound SVAK-12 on  
42 potentiation of BMP-2 activity over the concentration range from 0.125 to 1.0 ug/ml  
43 while keeping the BMP-2 concentration at 1 ng/ml in the luciferase reporter assay  
44 (**Fig. 6**). SVAK-12 caused a dose-dependent enhancement of the luciferase activity  
45 with an optimum enhancement of 3.8-fold ( $P<0.05$ ) observed at a concentration of  
46 1.0  $\mu\text{g/ml}$  when compared to BMP-2 alone. The concentration required for  
47 half-maximal activation,  $\text{EC}_{50}$  value, of 2.6  $\mu\text{M}$  was calculated from the Hill plot. The  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8 EC<sub>50</sub> value was generated from fitted curves by solving for the x-intercept at the  
9  
10 50% activity level of the Y-intercept as described in methods. The non-sigmoidal  
11  
12 nature of the dose response curves of the compound is due to cell liting induced at  
13  
14 concentrations at or just above the maximal effective dose. After assay optimization,  
15  
16 which included determining optimal BMP-2 concentration, plating density of cells,  
17  
18 and compound incubation time, the promoter assay was shown to display the  
19  
20 dynamic range and reproducibility required for a screening assay.  
21  
22  
23  
24  
25  
26

27 *BMP-2 induced alkaline phosphatase and osteocalcin mRNA levels are enhanced*  
28  
29  
30 *by the compound SVAK-12*  
31  
32  
33

34 We tested whether the compound, SVAK-12, that enhanced BMP-induced  
35  
36 reporter activity would also exhibit potentiating activity on BMP-2-induced marker  
37  
38 gene expression. We determined the effectiveness of compound SVAK-12 over the  
39  
40 concentration range from 0.125 to 1.0 ug/ml while keeping the BMP-2 concentration  
41  
42 constant at 20 ng/ml by determining alkaline phosphatase mRNA levels (**Fig. 7**).  
43  
44 SVAK-12 caused a dose-dependent increase in the BMP-induced alkaline  
45  
46 phosphatase mRNA level with the maximal 3.5-fold increase ( $P<0.05$ ) compared to  
47  
48 BMP-2 alone observed at a compound with a maximal concentration of 1.0 µg/ml.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 in the absence or the presence of DMSO (0.01%), respectively, when compared to  
8  
9 the „no treatment’ control (**Fig. 7**).

10  
11  
12  
13  
14 We also tested whether the compound, SVAK-12, that enhanced  
15  
16 BMP-induced reporter activity and ALP mRNA expression would exhibit potentiating  
17  
18 activity by increasing BMP-2-induced osteocalcin gene expression. Such an  
19  
20 observation would strengthen its biological role in promoting the osteoblastic  
21  
22 phenotype. We determined the effectiveness of compound SVAK-12 over the  
23  
24 concentration range from 0.125 to 1.0 ug/ml while keeping the BMP-2 concentration  
25  
26 constant at 20 ng/ml, as shown in **Fig. 8**. SVAK-12 caused a dose-dependent  
27  
28 increase in the BMP-induced osteocalcin mRNA level with a maximal 4.4-fold  
29  
30 increase ( $P<0.05$ ) compared to BMP-2 alone observed at a compound  
31  
32 concentration of 1.0  $\mu\text{g/ml}$ . BMP-2 alone induced a 9-fold or 7-fold increase in  
33  
34 osteocalcin mRNA in the absence or the presence of DMSO (0.01%), respectively,  
35  
36 when compared to „no treatment control’(**Fig. 8**). An  $\text{EC}_{50}$  value in the range of 1.5  
37  
38 to 5.3  $\mu\text{M}$  was estimated for the expression of both alkaline phosphatase and  
39  
40 osteocalcin mRNAs.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 *BMP-2 induced ALP enzyme activity is enhanced by the compound SVAK-12*  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 We used SVAK-12 in the concentration range of 0.125 to 1.0  $\mu\text{g/ml}$  while  
8  
9 keeping the BMP-2 concentration constant at 50  $\text{ng/ml}$  to evaluate its enhancement  
10  
11 of the BMP-induced alkaline phosphatase activity. The ALP enzyme activity assay  
12  
13 demonstrated that the compound dose-dependently enhanced the BMP-2 induced  
14  
15 ALP activity. The peak activity of the maximal 4.8-fold increase ( $P<0.001$ ) was  
16  
17 observed at a compound concentration of 1.0  $\mu\text{g/ml}$  when compared to BMP-2  
18  
19 alone, further confirming the earlier observations (**Fig. 9**). An  $\text{EC}_{50}$  value of 3.7  $\mu\text{M}$   
20  
21 was estimated for the activity of alkaline phosphatase. These results support our  
22  
23 hypothesis that SVAK-12 is potentially a low-cost substitute for a recombinantly  
24  
25 prepared protein in enhancing BMP-induced osteoblastic responses in cells.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## DISCUSSION

Increasing cellular responsiveness to BMP would be advantageous since bone formation in humans is requiring such high dose of rhBMPs. LMP-1 is an example of a naturally occurring protein that increases cellular response to BMPs. In this study, we sought to find a synthetic compound that blocks Smurf1 activity to enhance BMP responsiveness. We identified a unique compound, SVAK-12, that promotes the BMP-induced expression of phenotypic markers characteristic of a differentiated osteoblast. The reporter assays using BMP-specific Smad1-driven 9×GCCG reporter plasmid, real-time RT-PCR for ALP and osteocalcin mRNA expression, and ALP enzyme activity assay all showed that the compound potentiated BMP-2 activity.

Small synthetic chemical compounds (under 700 Daltons), can be more easily manufactured than recombinant proteins and are more amenable to production and scale-up for low-cost use. Small-molecule compounds with potential BMP-potentiating activity will provide a pharmacological approach to help further extend the therapeutic use of BMPs. Any identification of a low cost compound that potentiates a BMP-induced cellular response will broaden the use of BMP-2 for efficient bone regeneration application. Therefore, we extended the use of our cell-based assay using the Smad1-specific luciferase reporter to test potentially



1  
2  
3  
4  
5  
6  
7 active candidates among the synthetic compounds that were selected as “leads”  
8  
9 after extensive chemo-informatic analyses of the Smurf1 WW2 domain and its  
10  
11 interacting site in target proteins. We selected SVAK-12 as one such active “lead”  
12  
13 candidates.  
14  
15  
16  
17  
18

19 To test the validity of the cell-based reporter assay further, we examined  
20  
21 the potentiating activity of SVAK-12 on BMP-2-induced cellular responses.  
22  
23 Real-time RT-PCR for ALP and osteocalcin mRNA expression and the ALP enzyme  
24  
25 assay in C2C12 cells also demonstrated a dose-dependent activity of SVAK-12 in  
26  
27 potentiating BMP-2 induced signaling. From these results we conclude that the  
28  
29 activity of SVAK-12 is not dependent on any particular assay as similar  
30  
31 BMP-potential effects were observed both in transfected and non-transfected  
32  
33 cells.  
34  
35  
36  
37  
38  
39  
40  
41

42 We applied lower concentrations of BMP-2 (0.125 - 5 ng/ml) than are  
43  
44 typically used (50-100 ng/ml) so as to improve the sensitivity of our reporter assay  
45  
46 in detecting enhancement of BMP-2 activity. We showed that the specificity of the  
47  
48 assay was well maintained despite monitoring multiple cellular outputs at various  
49  
50 time points. The compound SVAK-12 elevated the BMP-2-induced response  
51  
52 significantly even at a dose of 0.1 µg/ml. The effective dose of compound remained  
53  
54 consistent (0.25 µg/ml) among multiple assays. This suggested that the biological  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 markers in C2C12 cells that we chose to investigate are tightly controlled by the  
8 same BMP-signaling pathway. All these studies suggest that the compound,  
9 SVAK-12 or a potentially more efficacious derivative, may be useful in potentiating  
10 the BMP-2 responsiveness of cells. The combined use of such a compound with  
11 BMP-2 may reduce the high doses of BMP-2 protein currently required for its  
12 effective clinical use. The abundance and low cost of SVAK-12 makes it a highly  
13 desirable drug-candidate. Thus, SVAK-12 may be a useful pharmacological tool  
14 that induces BMP-mediated osteoblastic progression.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 In summary, we established the 9xGCCG reporter transfected C2C12 cells  
31 as a sensitive cell-based sensor of BMP-2 osteogenic effects. This system allowed  
32 us to monitor successfully the complex process of BMP-induced transdifferentiation  
33 of C2C12 cells towards the osteoblastic phenotype by determining various cellular  
34 markers at different time points in living cells. Also the identification and activity  
35 determination of SVAK-12 through novel chemo-informatics approach, virtual  
36 screenings and cell-based biochemical evaluations lay promising ground for further  
37 applications in bone biology. Future experiments will evaluate enhancement of  
38 BMP-2-induced bone formation by SVAK-12 or its more efficacious derivatives in  
39 animal models.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8 Our results provide support for the idea that low molecular-weight  
9  
10 compounds can inhibit protein–protein interactions that normally occur over  
11  
12 relatively large surfaces. Also, our results raise the possibility of developing drugs  
13  
14 that target Smurf1 via a novel mode of action and may inspire future rational  
15  
16 development of compounds with the ability to modulate WW domain-dependent  
17  
18 functions in other proteins. The rational development of compound SVAK-12 proves  
19  
20 that small-molecule compounds can provide all the necessary requirements to  
21  
22 block Smurf1 function. Currently, the compound selected in this study forms the  
23  
24 basis of a medicinal chemistry effort to produce new chemical entities with  
25  
26 optimized drug-like properties such as potency and bioavailability. Such compounds  
27  
28 could have future applications in the treatment of disease by specifically modulating  
29  
30 the WW domain-dependent interactions of a target protein. However, a major  
31  
32 challenge is to further develop such compounds into high-affinity, specific and  
33  
34 active drugs at low concentrations.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## DISCLOSURES

All the biochemical studies in this work were performed at the Atlanta Veterans Affairs Medical Center and partly supported by NIH grant # R01 AR53093 (Boden) and a VA Merit award to Dr. Titus. In the past and not related to this work, Dr. Boden has received compensation as a consultant for Medtronic Sofamor Danek and for intellectual property. Emory University and some of the authors have/may receive royalties in the future related to LMP-1. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. We thank Boojala VB Reddy for assistance in homology modeling. We also thank Vandana Voleti for assistance in computational analyses.

## LEGENDS

**Fig. 1.** Optimized structure of the WW2 domain of Smurf1. The anti-parallel  $\beta$ -sheet structures are shown in ribbon form.

**Fig.2.** Surface region of the Smurf1-WW2 domain is shown where the CAP small molecules are targeted. A group of consensus high scoring molecules are shown interacting with Smurf1-WW2 domain residues. The WW2 domain atoms are shown in stick form while the compounds are shown in ball and stick form.

**Fig.3.** Binding poses are shown for four selected high scoring low-molecular weight molecules that were in the pool of 300 consensus high scoring molecules used for virtual testing. The WW2 domain atoms are shown in stick form while the compounds are shown in ball and stick form.

**Fig. 4.** Determination of BMP-2 activity in a cell-based reporter assay. A dose-dependent induction of luciferase activity by BMP-2 is shown in C2C12 cells transfected with the BMP-specific and Smad1-driven 9×GCCG reporter plamid for 24 hr. Luciferase activities were determined in triplicate. \*Denotes statistical significance, determined as described in methods, between the indicated treatments ( $P<0.05$ ).

1  
2  
3  
4  
5  
6  
7  
8 **Fig. 5.** Determination of the efficacy of various selected compounds to enhance  
9  
10 BMP-induced luciferase activity. Relative activities of a representative set of  
11  
12 compounds in the luciferase reporter assay are shown. Compounds were tested at  
13  
14 a concentration of 1.0 ug/ml while BMP-2 was used at 1.0 ng/ml. The 1.0 µg/ml  
15  
16 compound concentration for screening was selected empirically. Data points were  
17  
18 determined in triplicate. In “no compound” controls, cells were treated with DMSO  
19  
20  
21 (0.01%) alone.  
22  
23  
24  
25  
26

27 **Fig. 6.** SVAK-12 potentiates BMP-2 responsiveness in the Smad1-driven reporter  
28  
29 assay. A 3.8-fold enhancement of luciferase activity was observed at a SVAK-12  
30  
31 concentration of 1.0 ug/ml when compared to BMP-2 alone (1 ng/ml). Data points  
32  
33 were determined in triplicate. Statistical significance from the BMP-2 control group  
34  
35 was ( $P < 0.05$ ) obtained as detailed in methods and is denoted by (\*).  
36  
37  
38  
39  
40  
41

42 **Fig. 7.** SVAK-12 enhances the BMP-induced increase of the ALP mRNA level in  
43  
44 C2C12 cells. The compound dose-dependently enhanced the BMP-2 induced ALP  
45  
46 mRNA level. The peak 3.5-fold enhancement of ALP mRNA level was observed at a  
47  
48 SVAK-12 concentration of 1.0 µg/ml. Quantitation of the mRNA was based on  
49  
50 triplicate determinations. \*Denotes significant difference from BMP alone in the  
51  
52 presence of an equal amount of DMSO (0.01%) as in compound treatments.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8 Statistical significance ( $P < 0.05$ ) among different groups was obtained as detailed in  
9  
10 the Methods section.

11  
12  
13  
14 **Fig. 8.** SVAK-12 enhances the BMP-induced osteocalcin mRNA level in C2C12  
15  
16 cells. The peak 4.4-fold enhancement of the osteocalcin mRNA level induced by  
17  
18 BMP-2 was observed at a SVAK-12 compound concentration of 1.0  $\mu\text{g/ml}$ .  
19  
20 Quantitation of mRNA was based on triplicate determinations. \*Denotes significant  
21  
22 difference from BMP alone in the presence of equal amount of DMSO (0.01%) as in  
23  
24 compound treatments. Statistical significance ( $P < 0.05$ ) among different groups was  
25  
26 obtained as detailed in Methods section.  
27  
28  
29  
30  
31

32  
33  
34 **Fig. 9.** Enhancement of BMP-2 induced ALP enzyme activity by SVAK-12. The  
35  
36 compound dose-dependently enhanced the ALP activity induced by 50 ng/ml of  
37  
38 BMP-2. The peak 4.8-fold enhancement of BMP-2-induced ALP activity was  
39  
40 observed at a SVAK-12 compound concentration of 1.0  $\mu\text{g/ml}$ . Data points were  
41  
42 determined in triplicate. \*Denotes significant difference from BMP alone control in  
43  
44 the presence of equal amount of DMSO (0.01%) as in compound treatments.  
45  
46 Statistical significance ( $P < 0.001$ ) among different treatment groups was obtained  
47  
48 as detailed in Methods.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**REFERENCES**

1. Chen D, Zhao M, Mundy GR. (2004) Bone morphogenetic proteins. *Growth Factors* 22: 233-241.
2. Polly DW Jr, Ackerman SJ, Shaffrey CI, Ogilvie JW, Wang JC, Stralka SW, Mafilios MS, Heim SE, Sandhu HS. (2003) A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. *Orthopedics* 26: 1027-1037.
3. Boden SD, Kang J, Sandhu H, Heller JG. (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. *Spine* 27: 2662-2673.
4. Boden SD, Schimandle JH, Hutton WC. (1995) The use of an osteoinductive growth factor for lumbar spinal fusion. Part I: Biology of spinal fusion. *Spine* 20: 2633-2644.
5. Kusumoto K, Bessho K, Fujimura K, Akioka J, Okubo Y, Wang Y, Iizuka T, Ogawa Y. (2002) Osteoinduction by recombinant human bone



1  
2  
3  
4  
5  
6  
7 morphogenetic protein-2 in muscles of non-human primates. J Int Med Res  
8  
9  
10 30: 251-259.

- 11  
12  
13  
14 6. Ackerman SJ, Mafilios MS, Polly DW Jr. (2002) Economic evaluation of bone  
15  
16 morphogenetic protein versus autogenous iliac crest bone graft in  
17  
18 single-level anterior lumbar fusion: an evidence-based modeling approach.  
19  
20  
21 Spine 27: S94-99.
- 22  
23  
24  
25  
26 7. Yamashita M, Ying S, Zhang G, Li C, Cheng SY, Deng C, Zhang Y. ( 2005)  
27  
28 Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by  
29  
30  
31  
32 targeting MEKK2 for degradation. Cell 121: 101-113.
- 33  
34  
35  
36 8. Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D. (2004) Smurf1  
37  
38 inhibits osteoblast differentiation and bone formation *in vitro* and *in vivo*. J.  
39  
40  
41 Biol. Chem. 279: 12854-12859.
- 42  
43  
44  
45 9. Sangadala S, Boden SD, Viggewarapu M, Liu Y, Titus L. (2006) LIM  
46  
47 mineralization protein-1 potentiates bone morphogenetic protein  
48  
49  
50 responsiveness via a novel interaction with Smurf1 resulting in decreased  
51  
52  
53 ubiquitination of Smads. J Biol Chem 281: 17212-17219.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
10. Sangadala S, Okada M, Liu Y, Viggewarapu M, Titus L, Boden SD. (2009) Engineering, Cloning and Functional Characterization of Recombinant LIM Mineralization Protein-1 Containing an N-terminal HIV-derived Membrane Transduction Domain. *Protein Expr Purif.* 65: 165-173.
11. Sangadala S, Boden SD, Metpally RP, Reddy BV. (2007) Modeling and analysis of molecular interaction between Smurf1-WW2 domain and various isoforms of LIM mineralization protein. *Proteins* 68: 690-701.
11. Bohm HJ. (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. *J. Comput. Aided Mol Des* 6: 61-78.
12. Sangadala S, Metpally RP, Reddy BV. (2007) Molecular interaction between Smurf1 WW2 domain and PPXY motifs of Smad1, Smad5, and Smad6--modeling and analysis. *J Biomol Struct Dyn* 25: 11-23.
13. Bohm HJ. (1992) The computer program LUDI: A new method for the de novo design of enzyme inhibitors. *J. Comput. Aided Mol Des* 6: 61-78.
14. Bohm HJ. (1994) On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure. *J Comput Aided Mol Des* 8: 623-632.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
15. Guex N and Peitsch MC. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis* 18: 2714-2723.
16. Schwede T, Kopp J, Guex N, and Peitsch MC. (2003) SWISS-MODEL: An automated protein homology-modeling server. *Nucleic Acids Res* 31: 3381-3385.
17. Okada M, Sangadala S, Liu Y, Yoshida M, Reddy BV, Titus L, and Boden SD. (2009) Development and optimization of a cell-based assay for the selection of synthetic compounds that potentiate bone morphogenetic protein-2 activity. *Cell Biochem Funct.* 27: 526-534.

Fig. 1





Fig. 2



**Fig. 3**




Fig. 4




Fig. 5A






Fig. 5B




Fig. 6




Fig. 7




Fig. 8





Fig. 9



Response:

Reviewer#1:

We thank the reviewer for recommending acceptance of manuscript as is.

Reviewer#2:

The compound, SVAK-12, at a dose of 2ug/ml or higher, resulted in reduced BMP-induced activity. This is because of lifting of cells from the culture-well surface rather than direct cell death caused by SVAK-12. The lifting of cells from plastic surface reduced the number of cells after cell harvesting thus yielding less protein and less BMP-induced activity. This is not really toxicity as much as exceeding the physiologic dose window. Similar cell effects can be seen with excessive doses of recombinant BMP-2 itself.

The compound database was initially curated to remove any toxic compounds. However, following the reviewer's advice, we performed ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) and TOPKAT analyses on the SVAK-12 structure, using the Discovery Studio Computational Tools (Accelrys, Inc., San Diego, CA) and determined the safe dose range for animal experiments. A complete assessment of toxicity of SVAK-12 and its chemical derivatives is beyond the scope of this 'lead identification strategy'- manuscript, but will be the subject of future studies.

Our senior author (SDB) and the other co-authors felt that there was too much emphasis on LMP-1, the structure of which was not really required in selecting the compound SVAK-12 from chemical database using *in silico* screening. Since we utilized WW domain structure and looked for complementary compounds that fit its binding pocket, (that is known to target all the known target proteins of Smurf1) for compound selection strategy, we edited the entire text to outline that strategy more clearly. Hence, we removed Fig.1. Fig. 2 and Fig. 3 are changed so that only a selected set of compounds used in the screening assays are shown. We believe that the changes made in the manuscript will improve its accuracy and quality. As the WW2 domain structure was more relevant than LMP-1 in compound selection, we edited the manuscript while preserving the selection strategy and the accuracy of all the statements, as these changes need to be brought up by us, the investigators, to improve overall quality of the manuscript. We regret the inconvenience caused by the uncorrected previous version.

Oct. 26, 2010

To

Editor

Mol. Cell Biochem.

Dear Sir: We are re-submitting the manuscript after thorough revision. We also addressed reviewer's comments. In the process, we passed due date by about a week as several of us were attending ASBMR 2010- conference in Toronto, Canada at the time of due date. Please kindly consider our manuscript as a revised manuscript. Thanking you.

Regards,

Dr. Sreedhara Sangadala